---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059042"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:28:31.125730+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Candel presents preclinical data at SITC for enLIGHTEN platform; Alpha-201-macro1 shows enhanced cancer cell killing

## Summary
- Preclinical data for enLIGHTEN Discovery Platform presented at SITC 2023 Annual Meeting in San Diego.
- Alpha-201-macro1, first experimental agent from platform, targets CD47/SIRPα pathway via local delivery.
- enLIGHTEN Advanced Analytics suite predicted multi-gene payload combinations from ICI-treated patient datasets.
- Viral chassis Alpha-201 armed with immunostimulatory payloads enhanced PBMC-mediated cancer cell killing in preclinical models.
- Data validate in silico prediction of payload combinations using human datasets to de-risk viral immunotherapy development.

## SEC filing metadata
- accession: 0000950170-23-059042
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023059042/0000950170-23-059042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023059042/cadl-20231104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059042
- JSON: https://secwatch.observer/filing/0000950170-23-059042.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.